Strong Investment Potential for NewAmsterdam Pharma’s Obicetrapib Due to Cardiovascular and Metabolic Benefits

Analyst Dennis Ding of Jefferies maintained a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report), retaining the price target of $45.00.

Dennis Ding’s rating is based on several compelling factors. Firstly, NewAmsterdam Pharma’s obicetrapib has demonstrated consistent absolute reductions in Lp(a) levels across various patient subgroups in its Phase III trials. This is significant because absolute reductions in Lp(a) are correlated with a decrease in major adverse cardiovascular events (MACE), enhancing the therapeutic value of obicetrapib.
Furthermore, the analysis from the BROADWAY study highlights obicetrapib’s impact on small LDL particles, showing a substantial reduction in small LDL-P levels. These particles are more atherogenic, and their reduction could contribute significantly to the observed MACE benefits. Additionally, obicetrapib’s potential protective effects against degenerative diseases like Alzheimer’s, as well as its role in preventing new-onset diabetes, further strengthen its investment appeal.

Ding covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Rhythm Pharmaceuticals, and Immunovant. According to TipRanks, Ding has an average return of -9.3% and a 33.90% success rate on recommended stocks.

In another report released today, RBC Capital also maintained a Buy rating on the stock with a $38.00 price target.